[Determinants of the cost of initiation of insulin therapy type&#160;2 diabetic patients in France: possible approaches to optimization].
Increased costs cannot be exclusively attributed to the consequences of insulin prescription. Any initiative designed to&#160;accelerate acquisition of patient autonomy would be likely to reduce the costs observed after switching to insulin, provided this initiative is adapted to the patient&#8217;s health profile, diabetes history and available medical resources.</ce:para>.